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Abstract
Background: Obstructive sleep apnea (OSA) has been associated with cardiovascular disease (CVD), but whether
OSA is an independent risk factor for CVD is controversial. The purpose of this study is to determine if patients
with OSA have subclinical cardiovascular disease that is detectable by multi-modality cardiovascular imaging and
whether these abnormalities improve after nasal continuous positive airway pressure (nCPAP).
Results: Of the 35 consecutive subjects with newly diagnosed moderate to severe OSA recruited from the
Stanford Sleep Disorders Clinic, 20 patients were randomized to active vs. sham nCPAP. Active nCPAP was titrated
to pressures that would prevent sleep disordered breathing based on inpatient polysomnography. OSA patients
had baseline vascular function abnormalities including decreased myocardial perfusion reserve (MPR), brachial flow
mediated dilation (FMD) and nitroglycerin-induced coronary vasodilation. Patients randomized to active nCPAP had
improvement of MPR (1.5 ± 0.5 vs. 3.0 ± 1.3, p = 0.02) and brachial FMD (2.5% ± 5.7% vs. 9.0% ± 6.5%, p = 0.03)
after treatment, but those randomized to sham nCPAP showed no significant improvement. There were no
significant changes seen in chamber sizes, systolic and diastolic function, valvular function and coronary
vasodilation to nitroglycerin.
Conclusions: Patients with moderate to severe OSA had decreased MPR and brachial FMD that improved after
3 months of nCPAP. These findings suggest that relief of apnea in OSA may improve microvascular disease and
endothelial dysfunction, which may prevent the development of overt cardiovascular disease. Further study in a
larger patient population may be warranted.
Background
Obstructive sleep apnea (OSA) has been associated with
an increased incidence of cardiovascular disease (CVD)
and these patients are, thus, likely to have a high burden
of subclinical disease [1,2]. However, the extent of sub-
clinical CVD has not been systematically evaluated.
Previous studies have used single measures of subclinical
disease [3-7]. In addition, whether OSA plays an inde-
pendent role in the development of CVD remains con-
troversial since most previous studies are cross sectional
and not randomized, and, thus, may not adequately
control for confounding factors.
We use multi-modality cardiovascular imaging (CVI)
to evaluate subclinical CVD in patients with OSA before
and after randomization to active or sham nasal contin-
uous positive airway pressure (nCPAP). We will (1)
determine the frequency of subclinical CVD using
multi-modality imaging in adults with newly diagnosed
moderate to severe OSA and (2) test the hypothesis that
nCPAP therapy, the standard treatment for OSA,
improves these abnormalities.
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Subjects
A total of 35 consecutive patients were recruited from
the patient population seen at the Stanford Sleep Disor-
ders Clinic. The inclusion criteria include: 1) newly diag-
nosed moderate to severe OSA as defined by the
American Academy of Sleep Medicine [8], 2) RDI ≥ 15
events per hour by inpatient polysomnography, and 3)
Epworth Sleepiness Scale score > 10. The exclusion cri-
teria include: 1) prior treatment for OSA, 2) an oxygen
saturation < 75% for > 10% of the diagnostic sleep study
or < 75% for > 25% of the first 4 hours of the diagnostic
sleep study, 3) clinical symptoms or diagnosis of coron-
ary artery disease, congestive heart failure, cardiac
rhythm disturbance, Raynaud’s disease (which is a con-
traindication for flow mediated dilation), respiratory dis-
ease, diabetes, chronic neurological disorders, cancer not
in remission, and renal failure, 4) metal objects, devices
or implants in or on the body including pacemakers,
aneurysm clips, prostheses, bullets, buckshot, shrapnel,
and any metal fragments from working around metal
(which are contraindications for cardiovascular magnetic
resonance imaging) and 5) contraindications to adeno-
sine or nitroglycerin. Seven participants failed the initial
screening for eligibility, and 8 withdrew prior to rando-
mization. The Stanford Institutional Review Board
approved the study. All subjects gave written informed
consent.
Recruitment, Randomization and Blinding
Subjects were identified for recruitment after undergoing
as t a n d a r do v e r n i g h tinpatient respiratory polysomno-
graphic sleep study. The diagnostic polysomnogram
served as the baseline measure. Patients also completed a
standard questionnaire to evaluate the degree of sleepi-
ness and underwent baseline echocardiography, cardiac
magnetic resonance imaging, and vascular ultrasound.
After baseline assessments, subjects were randomized to
either active (therapeutic)o rs h a m( s u bt h e r a p e u t i c )
nCPAP and then admitted for a second night of polysom-
nography for nCPAP titration. During the nCPAP titra-
tion night, if patients were randomized to active nCPAP,
pressures were varied throughout the night to control the
patients’ sleep disordered breathing. For those on sham
nCPAP, pressures fluctuated slightly but no more than
0.5 cm H2O pressure, which was achieved by inserting a
flow restricting connector at the machine outlet and six
extra 4 mm holes in the collar of the main tubing at the
end of the mask to allow air to escape and to prevent re-
breathing of carbon monoxide. A certified technician
reviewed the polysomnograms the next day to determine
the optimal therapeutic pressure to control snoring and
sleep apnea for patients in the active nCPAP group.
Patients assigned to sham nCPAP received a similar
nCPAP device but the machine delivered air pressure
insufficient to prevent sleep disordered breathing. In all
other ways, the nCPAP machines were similar. The
patients, technicians conducting the titration studies and
investigators assessing the imaging studies were not
aware of treatment group assignments. Thus, the study
was effectively double-blind.
Within 7 days after the assessment, the patients were
given their nCPAP machines and instructed how to use
the machines at home. Study staff contacted patients
m o n t h l yt oa s s e s sa d h e r e n c et ot h ed e v i c e s .P a t i e n t s
returned after three months for repeat polysomnogram
and multi-modality CVI studies. Information on compli-
ance was downloaded from the assigned nCPAP
machines at the end of the study.
Polysomnography
Overnight respiratory polysomnographic sleep studies
were performed at baseline, for nCPAP titration, and
after treatment. An obstructed breathing event consisted
of an obstructive apnea, hypopnea, or respiratory effort-
related arousals [9]. Moderate or severe apnea was
defined as a respiratory disturbance index > 15 events
per hour of sleep.
Echocardiography
Echocardiographic images were obtained in standard
views by the same experienced sonographer (Hewlett
Packard, Sonos, 5500). Left ventricular diastolic function
and pulmonary arterial pressure was assessed by Dop-
pler echocardiography in accordance with the American
Society of Echocardiography recommendations [10].
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) included an
assessment of structure and function, adenosine stress
myocardial perfusion, and coronary artery vasodilation
to nitroglycerin (NTG). Imaging analysis was performed
using Report Card, the GE software.
Scans were performed using a 1.5T Signa MR scanner
(GE Healthcare, Milwaukee, WI) equipped with high-
performance gradients (40 mT/m, 150 mT/m/ms).
A commercial 4-channel cardiac phased-array surface
coil provided signal reception (GE Healthcare, Milwau-
kee, WI). A real-time interactive system (iDrive, GE
Healthcare, Milwaukee, WI) was used for localization.
Assessment of cardiac function was obtained using an
ECG-triggered retrospectively gated cine SSFP sequence
(20 phases per cardiac cycle, TR = 3.6 ms, TE = 1.6 ms,
FOV = 280 to 390 mm and flip angle = 40°). First-pass
myocardial perfusion imaging was performed using a
segmented echo-planar imaging pulse sequence with a
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sine was administered intravenously at a rate of
140 mcg/kg/min for 4 minutes, followed by first-pass
myocardial perfusion imaging during intravenous injec-
tion of 0.1 mmol/kg gadolinium-DPTA at a rate of
5 ml/s. Rest perfusion images were acquired approxi-
mately 10 minutes after stress images. The following
perfusion pulse sequence parameters were used: TR =
2.4 ms, TE = 1.2 ms, inversion time = 158 to 211 ms,
e c h ot r a i nl e n g t h=4t o8m s ,F O V=3 4t o3 7×2 5t o
27 cm, matrix = 128×128, flip angle = 25°, and slice
thickness = 10 mm. The rest perfusion images were
generally acquired with the same graphic prescription
used for the stress images. For analysis of myocardial
perfusion, signal intensity was determined for each of
the three contiguous slices representing the base, mid
and apex of the left ventricle. The signal intensity before
contrast agent administration was subtracted, and the
upslope of the resulting signal intensity time curve was
determined. A perfusion score was generated by adding
the upslope of each of the three slices. The myocardial
perfusion reserve (MPR) was calculated as the ratio
between the myocardial perfusion score at stress divided
by the myocardial perfusion score at rest.
NTG-induced coronary vasodilation was then per-
formed. Using a real-time interactive system, in-plane
views of the right coronary artery (RCA) were prescribed.
A cross-sectional view of the most linear portion of the
proximal to mid RCA was prescribed. Multi-slice high-
resolution spiral coronary magnetic resonance angiogra-
phy was performed with cardiac gating, breath-holding,
and acquisition during diastole (FOV = 22 cm, in-plane
spatial resolution = 0.7 mm, slice thickness = 5 mm,
3 slices, TR = 1 heart beat, TE = 2.5 ms, 18 interleaves,
and flip angle = 60°). Cross-sectional spiral high-resolu-
tion coronary magnetic resonance angiography images
[12] were acquired before and 5 minutes after adminis-
tration of 0.4 mg sublingual NTG while the patient was
inside the magnet.
Using the cross-sectional RCA images, the most circu-
lar and corresponding slices were identified on the pre-
and post-NTG images. These images were all pooled
and then randomized, with neither patient nor NTG
information provided on the images. We used a custom
designed software program to analyze the cross sectional
images. Images were magnified two-fold, and an ovoid
region of interest tool was used to trace around the
RCA, yielding the cross-sectional area.
Vascular Ultrasound
Endothelial function was assessed non-invasively using
vascular ultrasound to measure brachial artery flow
mediated dilation (FMD) following reactive hyperemia
in accordance with published guidelines [13]. Studies
were performed by one of two trained operators. Studies
were performed at the same time of day and in the fast-
ing state. Vasoactive medications were held 24 hours
prior to the study.
Brachial artery diameters were measured using an
automated software system to detect near and far wall
edges and measure vessel diameter for each frame in the
10-second loop (Vascular Analysis Tools, Medical Ima-
ging Applications, Iowa, USA). All analyses were per-
formed by one of two trained operators. Previous
reproducibility studies indicate high operator agreement.
Sample Size Calculation
The sample size was estimated based on a previous ran-
domized study comparing FMD in patients with moder-
ate to severe OSA randomized to 3 months of nCPAP
and no nCPAP [14]. FMD was significantly lower in
patients randomized to nCPAP (nCPAP 8.9 ± 1.9%, no
nCPAP 5.0 ± 0.7%, p = 0.02). Using a two tailed a =
0.01 and power of 0.90, an attrition rate of 20%, the esti-
mated sample size is 10 subjects per each group (total
number of subjects is 20).
Statistical Analysis
Continuous variables were reported as means with stan-
dard deviations. Categorical variables were reported as
frequencies and counts. Standard thresholds for abnor-
mal values were used for all parameters. An MPR < 2.5
was considered abnormal. This cut off value is chosen
based on a review of studies by Koch, which showed
that arteries with significant narrowing (> 70%) had a
flow reserve less than 2.5 [15]. An MPR of < 2.5 was,
therefore, selected for the most significant flow impair-
ment. A global MPR < 2.5 was also used as the cutoff in
the Multi-Ethnic Study of Atherosclerosis (MESA), a
population-based prospective cohort study of subclinical
cardiovascular disease and its progression [16]. A change
of < 9% and < 15% in the brachial artery diameter after
FMD and in the coronary artery cross sectional area
after NTG were considered abnormal, respectively.
These cutoff values were chosen based on a study in
228 non diabetic subjects who were matched for age
and gender. The study showed that flow mediated dila-
tion (8.5% ± 5.3% versus 11.7% ± 6.3%, p < 0.001) and
NTG-mediated vasodilation (14.9% ± 6.0% vs. 18.5% ±
7.8%, p = 0.003) were both impaired in hypertensive
compared to normotensive individuals [17].
The differences between clinical characteristics and
compliance between patients receiving active and sham
nCPAP were assessed by unpaired Student’stt e s ta n d
Chi square test for continuous and categorical variables,
respectively. Multi-modality imaging parameters were
compared before and after treatment using paired
Student’s t test and McNemar’s test for continuous and
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stolic function parameters using the McNemar’st e s t ,
categories were collapsed into normal and abnormal.
Specifically, the following were considered normal: E/A
> 0.75 and < 1.5, DT = 140 - 240 ms, E prime < 8 cm/s
and a pulmonary vein pattern that was not diastolic pre-
dominant. Other values were considered abnormal. Lin-
ear regression analysis was performed to determine the
relationship between the RDI and the following variables
measured at baseline: 1) MPR, 2) NTG-induced coron-
ary vasodilation, and 3) FMD. A two-tailed p value
< 0.05 was considered statistically significant. Statistical
analyses were performed with SPSS software version
13.0 (SPSS, Inc. Chicago, IL).
Results
Demographic and Clinical Characteristics
There were no significant differences between baseline
characteristics between the two groups (Table 1). The
average age of subjects was 53.4 ± 11.2 years. The major-
ity of patients were Caucasian males who were over-
weight and nonsmokers with hypertension. There were
no significant differences between patients randomized
to active vs. sham nCPAP in the RDI (37.7 ± 19.4 vs. 36.2
± 17.0, p = 0.87) and apnea hypopnea index (38.8 ± 21.38
vs. 31.6 ± 11.14, p = 0.79). There was no significant dif-
ference after adjustment for sleep duration in patients
randomized to active vs. sham nCPAP for obstructive
apneas (84.4 ± 89.0 vs. 35.3 ± 29.7, p = 0.12), total apneas
(85.1 ± 89.5 vs. 39.8 ± 28.8, p = 0.17) and total hypopneas
(149.2 ± 33.8 vs. 130.0 ± 63.2, p = 0.41), respectively.
Except for changes in high density lipoprotein levels,
there were no significant differences between the two
groups before and after nCPAP (Table 2).
Polysomnography
Compliance with nCPAP was equivalent in both groups
w i t ht h ea v e r a g eu s ep e rn i g h to f5 . 1±1 . 9h o u r sa n d
4.9 ± 2.3 hours in the active and sham groups, respec-
tively (p = 0.9). Changes in polysomnography measure-
ments before and after treatment are shown in Table 3.
Echocardiography
Echocardiography assessment was performed success-
fully in 20/20 patients, respectively. Seven patients with
OSA had at least one diastolic parameter that was sug-
gestive of diastolic dysfunction. Four patients had signif-
icant valvular abnormalities including 3 patients with
significant aortic regurgitation and one patient with sig-
nificant mitral regurgitation. Most patients had inade-
quate tricuspid regurgitation to estimate right
ventricular systolic pressures, but of those with measur-
able values, all (8/8) had normal pulmonary pressures.
Patients randomized to active nCPAP had significant
improvement in the E/A ratio after treatment; whereas,
those randomized to sham nCPAP did not. Changes in
echocardiographic parameters before and after nCPAP
are shown in Table 4.
Table 1 Demographics and Clinical Characteristics
Sub therapeutic nCPAP
(n = 10)
Therapeutic nCPAP
(n = 10)
All Patients
(n = 20)
p value
Age, years 53.9 ± 10.8 52.9 ± 11.6 53.4 ± 11.2 0.85
Male 10/10 8/10 18/20 0.47
Caucasian 6/10 6/10 12/20 1.00
BMI, kg/m
2 29.6 ± 5.6 30.1 ± 4.7 29.8 ± 5.2 0.85
Smoking 0/10 1/10 1/20 1.00
HTN 10/10 10/10 20/20 1.00
DM 1/10 0/10 1/20 1.00
Dyslipidemia 5/10 4/10 9/20 1.00
# Awakenings During Night 1.35 ± 0.98 2.1 ± 0.6 1.7 ± 0.9 0.07
# Hours of Sleep on Weekday Nights 7.15 ± 1.32 7.53 ± 0.81 7.34 ± 1.11 0.48
# Hours of Sleep on Weekend Nights 6.93 ± 2.43 7.7 ± 1.12 7.34 ± 1.11 0.40
# Naps ≥ 5 minutes Per Week* 1.7 ± 2.25 1.1 ± 1.46 1..4 ± 1.92 0.51
Feels Unrested During Day* 1.8 ± 1.2 1.2 ± 0.87 1.15 ± 1.2 0.25
Feel Excessively Sleepy During Day* 1.8 ± 0.87 1.3 ± 0.64 1.56 ± 0.80 0.18
Do Not Get Enough Sleep* 2.4 ± 0.8 2.0 ± 0.89 2.2 ± 0.87 0.33
Feel Excessively Fatigued During Day* 2.3 ± 1.27 1.6 ± 0.92 1.95 ± 1.16 0.20
# Caffeinated Beverages Per Week 1.9 ± 1.5 1.05 ± 0.57 1.5 ± 1.2 0.13
# Alcoholic Beverages Per Week 4.3 ± 5.2 2.1 ± 5.01 3.2 ± 5.2 0.37
p values reflect differences in scores between Post nCPAP minus Baseline for the Active vs. Sham Groups
* 0 = never; 1 = rare (1/month or less); 2 = sometimes (2-4/month); 3 = often (5 - 15/month); 4 = almost always (16-30/month)
BMI: body mass index, HTN: hypertension, DM: diabetes
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Assessment of cardiac structure and function was suc-
cessfully performed in 20/20 patients with no significant
differences in cardiac structure and function between
the two groups (Table 5). Except for LV ejection frac-
tion, there was no significant change in chamber sizes,
end diastolic volumes, right ventricular ejection fraction,
and LV mass after 3 months of therapy.
Adenosine stress perfusion CMR was successfully per-
formed in 16/20 patients. No patients had adverse cardi-
ovascular events during adenosine stress study. No
regional myocardial perfusion defects were noted by
qualitative visual assessment in either group.
Baseline MPR was abnormal in patients with sleep
apnea with no significant differences between subjects
randomized to active and sham. There was no significant
correlation between baseline RDI and MPR (r = 0.32,
p = 0.24). Three months after randomization, the MPR
increased significantly in patients randomized to active
nCPAP (1.5 ± 0.5 vs. 3.0 ± 1.3, p = 0.02); however, it did
not change significantly in patients randomized to sham
nCPAP (2.0 ± 1.2 vs. 2.5 ± 1.1, p = 0.38 (Table 5).
Table 2 Clinical Parameters Before and After Treatment
Baseline Treatment Before vs. After Treatment
Pairwise Comparison (p value)
Active Sham p Active Sham p Active Sham
Average SBP, mmHg 121.0 ± 11.6
(10/10)
127 ± 10.3
(10/10)
0.26 126.0 ± 15.8
(10/10)
130.4 ± 14.2
(10/10)
0.54 0.55 0.33
Average DBP, mmHg 75.2 ± 11.1
(10/10)
78.9 ± 11.4
(10/10)
0.11 83.9 ± 10.6
(10/10)
78.7 ± 11.2
(10/10)
0.97 0.34 0.06
Fasting glucose 99.5 ± 17.1
(10/10)
91.1 ± 13.9
(9/10)
0.27 101.6 ± 18.7
(10/10)
91.6 ± 19.3
(9/10)
0.28 0.96 0.92
2 hour Fasting Glucose 142.3 ± 64.3
(10/10)
109.1 ± 58.6
(9/10)
0.26 140.5 ± 38.4
(10/10)
120.0 ± 55.6
(9/10)
0.39 0.89 0.58
LDL, mg/dl 105.3 ± 16.7
(9/10)
109.4 ± 30.4
(8/10)
0.75 114.6 ± 34.3
(9/10)
107.1 ± 40.0
(8/10)
0.89 0.45 0.75
HDL 47.1 ± 18.5
(10/10)
42.2 ± 15.0
(10/10)
0.56 42.0 ± 15.9
(10/10)
40.1 ± 9.0
(10/10)
0.78 0.04 0.86
Cholesterol/HDL 4.1 ± 1.3
(10/10)
5.0 ± 2.4
(10/10)
0.31 4.9 ± 1.8
(10/10)
4.6 ± 1.7
(10/10)
0.86 0.12 0.15
Triglycerides 148.0 ± 128.4
(10/10)
172.9 ± 200.4
(10/10)
0.76 145.8 ± 86.0
(10/10)
173.9 ± 206.8
(10/10)
0.71 0.96 0.92
SBP: systolic blood pressure, DBP: diastolic blood pressure, LDL: low density lipoprotein, HDL: high density lipoprotein
Table 3 Polysomnography Before and After Treatment
Baseline Treatment Before and After Treatment
Pairwise Comparison (p value)
Active Sham p Active Sham p Active Sham
RDI 37.7 ± 19.4 36.2 ± 17.0 0.87 2.2 ± 1.5 37.4 ± 23.3 0.0003 0.0004 0.91
Obstructive events 84.4 ± 89 35.3 ± 29.7 0.13 0.8 ± 1.6 71.2 ± 115 0.08 0.02 0.4
OEI 13.6 ± 15.2 7.4 ± 5.9 0.21 0.11 ± 0.22 10.6 ± 16.4 0.07 0.03 0.59
AHI 38.8 ± 21.38 31.6 ± 11.14 0.79 2.2 ± 1.5 37.4 ± 23.3 0.0003 0.0004 0.89
Sleep Efficiency 80.2 ± 8.6 73.8 ± 13.1 0.23 87.4 ± 6.8 86.7 ± 7.6 0.84 0.02 0.002
Sleep Latency (min) 17.2 ± 19.6 16.7 ± 17.0 0.77 8.3 ± 9.5 9.54 ± 6.6 0.89 0.1 0.03
Total Sleep Time, min 379.2 ± 48.8 291 ± 81.5 0.01 408.2 ± 51.3 377.9 ± 66.7 0.27 0.18 0.04
NREM I, % of TST 10.84 ± 8.0 12.5 ± 10.9 0.65 9.5 ± 5.0 3.2 ± 0.6 0.6 0.50 0.20
NREM II, % TST 67.0 ± 11.3 58.2 ± 27.4 0.35 69.6 ± 6.3 70.8 ± 4.5 0.62 0.60 0.80
NREM III, % TST 2.7 ± 5.8 0.94 ± 1.9 0.39 1.6 ± 1.9 2.0 ± 0.8 0.74 0.62 0.16
NREM, IV, % TST 0.05 ± 0.15 0.71 ± 1.4 0.17 0.9 ± 1.7 0.2 ± 0.1 0.14 0.17 0.37
REM, % of TST 18.9 ± 7.4 14.1 ± 7.3 0.18 17.7 ± 5.1 2.8 ± 0.4 0.40 0.70 0.38
Minimal nocturnal SaO2 82.3 ± 5.5 83.8 ± 11.5 0.17 93.4 ± 2.3 86.1 ± 7.8 0.01 0.13 0.28
SaO2 < 90%, % of TST 8.0 ± 14.4 4.1 ± 0.3 0.28 0.07 ± 0.2 5.7 ± 7.4 0.03 0.0003 0.05
RDI: respiratory disturbance index defined as the number of events that distrupt sleep divided by the sleep duration in hours;
OEI: obstructive events index defined as the number of obstructive events divided by the sleep duration in hours.
AHI: apnea-hypopnea index defined as the number of apnea-hypopnea events divided by the sleep duration in hours.
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Baseline Treatment Before vs. After Treatment: Pair-wise Comparison (p value)
Active Sham Active Sham Active Sham
E wave, cm/s
≤ 1 cm/s 90% (9/10) 100%(10/10) 90% (9/10) 80% (8/10)
> 1 cm/s 10% (1/10) 0% (0/10) 10% (1/10) 20% (2/10)
p value 1.0 1.0 1.0 0.25
E/A ratio
≤ 0.75 40% (4/10) 10% (1/10) 0% (0/10) 20%(2/10)
> 0.75 & < 1.5 30% (3/10) 90%(9/10) 90%(9/10) 60%(6/10)
≥1.5 30%(3/10) 0%(0/0) 10% (1/10) 20%(2/10)
p value 1.0 1.0 0.03 0.25
DT
< 140 ms 0 (0/10) 0 (0/10) 0 (0/10) 0 (0/10)
140-240 ms 60% (6/10) 80% (8/10) 90% (9/10) 70%(7/10)
> 240 ms 40% (4/10) 20% (2/10) 10%(1/10) 30%(3/10)
p value 0.62 0.33 1.00 1.00
E’
≤ 8 cm/s 11% (1/9) 20%(2/10) 11% (1/9) 40% (4/10)
> 8 cm/s 89% (8/9) 80%(8/10) 89%(8/9) 60%(6/10)
p value 0.92 0.30 1.00 0.25
E/e’
< 8 66.7% (6/9) 50% (5/10) 44% (4/9) 60% (6/10)
8-15 33.3%(3/9) 50%(5/10) 56%(5/9) 40%(4/10)
> 15 0% (0/10) 0% (0/10) 0% (0/10) 0% (0/10)
p value 0.90 0.66 0.5 0.5
S/D ratio
S > D 50%(4/8) 40% (2/5) 5/8 (50%) 40% (2/5)
S = D 50%(4/8) 60% (3/5) 3/8(30%) 60% (3/5)
S < D 0% (0/8) 0 (0/5) 0 (0/8) 0 (0/5)
p value 1.00 0.59 1.00 1.00
E: peak velocity associated with early mitral filling, A: peak velocity associated with the atrial kick, DT: deceleration time, E’: E prime by tissue doppler, S: peak
systolic velocity associated with the pulmonary vein flow, D: peak diastolic veolicty associated with pulmonary vein flow
Table 5 Cardiac Structure and Function, Myocardial Perfusion Reserve and Coronary Artery Vasoreactivity by Magnetic
Resonance Imaging
Baseline Treatment Before vs. After Treatment
Pairwise Comparison (p value)
Active Sham p Active Sham p Active Sham
LV Mass 106.1 ± 28.9 108.3 ± 23.6 0.86 111.34 ± 39.8 118.4 ± 25.0 0.66 0.36 0.18
LV Mass/BSA 52.2 ± 11.4 49.3 ± 7.9 0.54 56.6 ± 18.4 69.9 ± 32.2 0.98 0.38 0.15
RVEDV 161.1 ± 28.6 171.8 ± 35.4 0.49 165.8 ± 38.1 181.6 ± 54.2 0.48 0.40 0.40
RVEDV/BSA 79.7 ± 13.0 79.1 ± 15.8 0.93 81.7 ± 79.4 82.6 ± 22.5 0.92 0.45 0.53
LVEDV 148.3 ± 32 158.3 ± 31.1 0.51 151.1 ± 30.5 163.4 ± 38.7 0.46 0.63 0.39
LVEDV/BSA 73.0 ± 13.5 72.3 ± 9.6 0.88 74.7 ± 13.4 74.4 ± 14.2 0.96 0.47 0.57
RV EF 58.9 ± 6.9 56.7 ± 9.0 0.57 55.5 ± 5.7 54.0 ± 11.4 0.80 0.26 0.43
LV EF 68.9 ± 7.1 67.4 ± 8.2 0.69 71.5 ± 4.6 65.1 ± 7.5 0.04 0.34 0.31
MPR 1.5 ± 0.5 2.0 ± 1.2 0.38 3.0 ± 1.3 2.5 ± 1.1 0.49 0.02 0.38
Change in CSA RCA, % 14+8 20 ± 10 0.16 18 ± 15 15 ± 8 0.58 0.46 0.23
LV: left ventricle, BSA: body surface area, RV: right ventricle, EDV: end diastolic volume, EF: ejection fraction, MPR: myocardial perfusion reserve, CSA: cross
sectional area, RCA: right coronary artery
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At baseline, the mean percent vasodilation to NTG was
abnormal, but did not significantly differ between the
two groups (Table 5). There was no significant correla-
tion between baseline RDI and NTG coronary vasodila-
tion (r = -0.14, p = 0.64). There was no significant
difference in coronary vasodilation after 3 months of
therapy in either the active or sham groups.
Vascular Ultrasound
Assessment of brachial artery FMD by vascular ultra-
sound was successfully performed in 18/20 patients.
Patients with OSA had impaired FMD with no signifi-
cant differences in brachial artery FMD at baseline in
the active vs. sham groups (Table 6). There was no sig-
nificant correlation between baseline RDI and FMD
(r = 0.08, p = 0.78). Three months after randomization,
FMD increased significantly and even normalized in the
active group (2.5 ± 5.7 vs. 9.0 ± 6.5, p = 0.03); however,
there was no significant improvement in the sham
group (4.0 ± 2.4 vs. 2.7 ± 2.4, p = 0.47). No significant
difference was detected in either group in NTG induced
vasodilatation of the brachial artery following 3 months
of therapy.
Discussion
This is the first study to provide a comprehensive eva-
luation of subclinical CVD using multi-modality CVI in
patients with OSA. As expected in asymptomatic
patients with moderate to severe OSA and no known
cardiovascular disease, most patients did not have signif-
icant abnormalities of cardiac structure and contractility.
Patients with OSA, however, had abnormal MPR and
brachial FMD, suggesting these patients have microvas-
cular disease and endothelial dysfunction, respectively.
These abnormalities improved after 3 months of active
nCPAP, providing further evidence that OSA may con-
tribute to the development of CVD.
Preserved Cardiac Structure and Function
Previous studies have shown that OSA adversely affects
the structure and systolic function of the left [18-20]
and right ventricle [19,21]. Patients with OSA have
recurrent increases in left ventricular (LV) afterload dur-
ing sleep that results from large negative intra-thoracic
pressure swings, hypoxemia and arousals from sleep.
Recurrent LV strain over several hours of apneas may
result in chronic LV dysfunction. Increased sympathetic
activity and hypoxemia also contribute to LV dysfunc-
tion. Improvement has been reported after nCPAP and
may be related to a reduction in nocturnal afterload. LV
dysfunction, however, appears to be a late complication
and was observed in < 10% of cases in a previous study
[18] and was not observed in this study.
Other abnormalities have been reported in patients
with OSA including an increase in LV mass [22,23] and
diastolic dysfunction [23]. However, a recent report [23]
has shown that these abnormalities did not correlate
with the apnea hypopnea index (AHI) or with oxygen
saturation but were associated with age, hypertension
and obesity. Consistent with these findings, most
patients in our study whose average age was 55 years
old and who were not obese (average body mass index <
30) had normal LV mass and diastolic function.
Although all patients had a history of hypertension, the
average blood pressure was normal and the majority of
patients had good control of their blood pressure with
prescribed medications.
Similarly, RV dysfunction may be a result of chronic
intermittent hypoxia and hypercapnia during apneic epi-
sodes. RV dysfunction may also be secondary to left
ventricular dysfunction as a result of increased afterload
and sympathetic activity, which causes secondary hyper-
tension. RV dysfunction [21] and elevated RVSP [24],
however, is an uncommon finding in patients with sleep
apnea and was not found in our study.
Estimates of ejection fraction, however, may not be
sensitive enough to detect early changes related to
obstructive sleep apnea. Previous studies [19] have
shown impairment of the left and right ventricular myo-
cardial performance index, which is derived by measure-
ment of the isovolumic contraction and relaxation times
and valvular ejection times. Improvement correlated
well with AHI, independent of confounders. Reduced
systolic and diastolic velocities [25] of the left and right
ventricle have also been observed in patients with OSA
and were noted to improve after six months of CPAP.
Future studies are needed to determine the clinical uti-
lity of these measures in the assessment of patients with
sleep apnea.
Table 6 Brachial Artery Reactivity by Vascular Ultrasound at Baseline and On Treatment
Baseline Treatment Before vs. After Treatment
Pairwise Comparison (p value)
Active Sham p Active Sham p Active Sham
% Brachial FMD 2.5 ± 5.7 4.0 ± 2.4 0.53 9.0 ± 6.5 2.7 ± 2.4 0.01 0.03 0.24
% NTG induced vasodilation 7.0 ± 5.0 9.0 ± 5.0 0.38 9.0 ± 7.0 7.0 ± 5.0 0.47 0.47 0.38
FMD: flow mediated dilation; NTG: nitroglycerin
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Patients with OSA
Microvascular disease and endothelial dysfunction are
the earliest manifestations of coronary heart disease and
can be found in patients without obstructive coronary
artery disease (CAD) or myocardial disease. Coronary
microvascular dysfunction has been previously described
in patients with risk factors for CAD. In a previous study,
coronary flow reserve was reduced by 21% in smokers
and normalized with vitamin C administration, an anti-
oxidant [26]. Impairment in coronary flow reserve has
also been shown in asymptomatic subjects with hyperch-
olesterolemia [27] and angiographically normal coronary
arteries with demonstrated reversibility with cholesterol
lowering strategies [28]. Similarly, in our study, patients
with OSA with no documented obstructive CAD and no
myocardial disease had impaired MPR. MPR improved in
patients randomized to active but not sham nCPAP,
suggesting that the presence of microvascular disease is
d u et oO S Aa n dn o tt ot h ep r e s e n c eo fc a r d i o v a s c u l a r
risk factors in these patients. To our knowledge, this is
the first study to show that patients with OSA have
microvascular disease measurable by CMR MPR, which
improves with therapeutic nCPAP.
Similarly, endothelial dysfunction has been described
in patient with coronary risk factors as well as those
with OSA. Previous studies have shown that patients
with OSA have impaired brachial artery dilation to acet-
ylcholine, an endothelial-dependent stimulus, compared
with control subjects [29,30]. A recent study showed
that endothelial function in OSA patients improved
after 3 months of nCPAP [31]. This study also demon-
strated that resting nitric oxide (NO) production was
higher after CPAP. Other studies have confirmed
improvement in peripheral endothelial function as early
as two weeks after CPAP and increases in plasma levels
of NO have been observed as early as one night after
nCPAP [32,33]. Our study confirms these findings. In
this study, patients with OSA had decreased brachial
FMD. Patients randomized to active nCPAP showed
improvement in brachial FMD; whereas, those rando-
mized to sham nCPAP showed no significant change. At
baseline and at 3 months, there were no significant
changes in cardiac risk factors except for high density
lipoprotein, which decreased in both groups. The signifi-
cance of which is unclear but may be related to inactiv-
ity secondary to nCPAP usage. This study supports that
relief of apneic events by nCPAP in patients with sleep
apnea improves endothelial function.
Several mechanisms [34] have been suggested to
explain the relationship between OSA and vascular
dysfunction. Evidence suggests that recurrent apnea-
hypopnea events in OSA patients are associated with
repetitive hypoxemia and reoxygenation, resulting in
increased production of reactive oxygen species. This
leads to increased intra and extra cellular oxidative
stress and breakdown of NO, resulting in vascular
dysfunction. The relationship between apnea and vascu-
lar dysfunction was further supported in a recent study
[35], which showed that regional myocardial perfusion
defects were present during periods of apnea in patients
with OSA without obstructive CAD but were not
present during daytime scintigraphy. In addition, the
presence of cardiac risk factors in OSA patients, includ-
ing insulin resistance, hypertension, and hyperlipidemia
adversely, impairs vascular function. Cardiac risk factors
are associated with increased oxidative stress [36].
Recruitment and differentiation of endothelial progeni-
tor cells is also impaired by cardiovascular risk factors,
preventing endothelial cell repair [37]. Finally, cardiac
risk factors have been associated with increased asym-
metric dimethylarginine [38], an endogenous eNOS
inhibitor produced by increased methylation of L argi-
nine, which decreases synthesis of NO, increases oxida-
tive stress and inhibits endothelial cell repair.
Study Limitations
A limitation of the study is the relatively small sample
size, which may decrease the power to detect abnormal-
ities in all clinical and imaging parameters. However,
with the small sample size, we were able to detect the
presence of microvascular disease and endothelial-
dependent function, suggesting that these abnormalities
are the most significant and earliest manifestation of
C V Di np a t i e n t sw i t hO S A .F u r t h e rs t u d yi nal a r g e r
population is warranted to confirm these findings.
Furthermore, we may not be applying the most sensitive
measures. Future studies, for example, could measure
myocardial performance index, a more sensitive mea-
sure of ventricular function. In addition, 3 months of
nCPAP may be inadequate to detect a significant
change in some cardiovascular outcomes such as left
ventricular mass, diastolic dysfunction, and pulmonary
HTN. However, it may not be ethical to withhold
nCPAP for a longer duration in this population. Future
studies with a longer therapeutic duration could be per-
formed in non-sleepy patients to determine if nCPAP is
effective to improve these parameters. Another limita-
tion of the study is that the duration of OSA may affect
the results of CVI studies. Although we recruit only
patients who are newly diagnosed, the duration that
they had undiagnosed OSA is unknown. The final lim-
itation of the study is that we are using imaging mea-
surements as surrogate measurements for outcome.
Findings from this initial study, however, may be
applied to design a large, prospective randomized trial
of nCPAP vs. sham CPAP to determine if nCPAP
improves cardiovascular outcomes.
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Page 8 of 10Conclusions
Our findings indicate that nCPAP therapy improves cor-
onary microvascular and endothelial function in OSA
patients. These findings suggest that nCPAP therapy
may prevent the development and progression of subcli-
nical atherosclerosis, and, thus, significantly reduce car-
diovascular morbidity and mortality in OSA patients.
Larger, well-designed, multi-center prospective studies
are needed to evaluate the impact of nCPAP therapy on
various cardiovascular outcomes in OSA patients.
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